However, in several cancers such as CESC, ESCA, CHOL, HNSC, pancreatic adenocarcinoma (PAAD), and skin cutaneous melanoma (SKCM), there was no statistically difference in PDE2A expression throughout the progression of tumors. This evidence concerns the gene PDE2A and cutaneous melanoma.